Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations
Ivosidenib plus nivolumab was safe with limited clinical benefit. Translational investigation highlights potential of IDH1 inhibition to alter tumor-immune interactions and provides hypotheses for future immune-checkpoint combinations.
Authors
- Carl Kim
- Aatur Dilip Singhi (ORCID: https://orcid.org/0000-0003-3930-7096)
- Riyue Bao (ORCID: https://orcid.org/0000-0002-6105-1704)
- Jan H. Beumer (ORCID: https://orcid.org/0000-0002-8978-9401)
- Diwakar Davar (ORCID: https://orcid.org/0000-0002-7846-8055)
- Megan Mantica (ORCID: https://orcid.org/0000-0002-6107-6696)
- Dan Paul Zandberg (ORCID: https://orcid.org/0000-0002-1002-8301)
- Julie Urban
- Yvonne S. Eisele (ORCID: https://orcid.org/0000-0002-3868-4327)
- Brian R. Isett (ORCID: https://orcid.org/0000-0002-1581-0706)
- M. Nguyen
- Rose Doerfler (ORCID: https://orcid.org/0009-0000-6536-0523)
- Jan Drappatz
- Erica S. Myers
- Jason J. Luke (ORCID: https://orcid.org/0000-0002-1182-4908)
- Robert A. Parise (ORCID: https://orcid.org/0000-0003-4398-6271)
- Rebekah Dadey (ORCID: https://orcid.org/0000-0001-9912-7893)
- Krishna B. Singh (ORCID: https://orcid.org/0000-0002-4052-4373)
- Liza Cosca Villaruz (ORCID: https://orcid.org/0000-0001-7456-523X)
- John C. Rhee
- Melissa Amber Burgess (ORCID: https://orcid.org/0000-0002-5753-1422)
- Lorenzo Sellitto
- Hong Wang (ORCID: https://orcid.org/0000-0003-0477-2908)
- Amy Goodman
- Steven J. Mullett (ORCID: https://orcid.org/0009-0005-6971-9288)
- Amy Rose
- Mark Jelinek
- Arjun Singh
Institutions
- Johns Hopkins University (US)
- University of Pittsburgh (US)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1093/oncolo/oyaf362
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00